← Back to Search
Expression Of Human Peroxiredoxin Isoforms In Response To Cervical Carcinogenesis.
Kiyoon Kim, Miran Yu, S. Han, I. Oh, Young-Jun Choi, Sungsoo S. Kim, K. Yoon, M. Jung, W. Choe
Published 2009 · Medicine, Biology
Save to my Library
Download via 🐼 PaperPanda Download via oaDOI Download via OAB Download via LibKey Download via Google Google ScholarAnalyze on Scholarcy Visualize in Litmaps
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Despite considerable progress in understanding the function of peroxiredoxin (Prx) in cancer, its expression patterns have not been extensively studied in response to cervical carcinogenesis. We evaluated the expression of Prx isoforms in normal tissue, cervical intraepithelial neoplasia (CIN1, CIN2, and CIN3), and cervical cancer. We found strong pattern of increased Prx II and III immunostaining with increasing severity of the lesion. No difference in staining intensity by grade of lesion was observed for Prx I, and IV. Therefore, we conclude that Prx II and III are upregulated in response to the development of cervical cancer.
This paper references
The isolation and purification of a specific "protector" protein which inhibits enzyme inactivation by a thiol/Fe(III)/O2 mixed-function oxidation system.
K. Kim (1988)
Stadtman : the isolation and purification of a specific ‘ protector ’ protein which inhibits enzyme inactivation by a thiol / Fe ( III ) / O 2 mixedfunction oxidation system
K Kim (1988)
Cloning, sequencing, and mutation of thiol-specific antioxidant gene of Saccharomyces cerevisiae.
H. Chae (1993)
Cloning , sequencing , and mutation of thiolspecific antioxidant gene of Saccharomyces cerevisiae
HZ Chae (1993)
From cytoprotection to tumor suppression: the multifactorial role of peroxiredoxins.
L. Butterfield (1999)
Peroxiredoxin I expression in human thyroid tumors.
T. Yanagawa (1999)
Peroxiredoxin I expression in oral cancer: a potential new tumor marker.
T. Yanagawa (2000)
Identification of a New Type of Mammalian Peroxiredoxin That Forms an Intramolecular Disulfide as a Reaction Intermediate*
M. S. Seo (2000)
Augmented expression of peroxiredoxin I in lung cancer.
J. Chang (2001)
Overexpression of peroxiredoxin in human breast cancer.
D. Y. Noh (2001)
GLOBAL VARIATION IN CANCER INCIDENCE AND MORTALITY
P. Notani (2001)
Cell specific expression of peroxiredoxins in human lung and pulmonary sarcoidosis
V. Kinnula (2002)
Overexpression of peroxiredoxins I, II, III, V, and VI in malignant mesothelioma
V. Kinnula (2002)
Overexpression of mitochondrial thioredoxin reductase and peroxiredoxin III in hepatocellular carcinomas.
J. H. Choi (2002)
Peroxiredoxin. Biol Chem
B Hofmann (2002)
Peroxiredoxins in breast carcinoma.
P. Karihtala (2003)
Essential role for the peroxiredoxin Prdx1 in erythrocyte antioxidant defence and tumour suppression
C. Neumann (2003)
Expression of peroxiredoxin II in vascular tumors of the skin: a novel vascular marker of endothelial cells.
S. Lee (2003)
Peroxiredoxins, a novel protein family in lung cancer
Siri T. Lehtonen (2004)
Peroxiredoxins, oxidative stress, and cell proliferation.
S. Immenschuh (2005)
Human mitochondrial peroxiredoxin 5 protects from mitochondrial DNA damages induced by hydrogen peroxide
Ingrid Banmeyer (2005)
Peroxiredoxin‐I is an autoimmunogenic tumor antigen in non‐small cell lung cancer
J. Chang (2005)
E: Peroxiredoxins, oxidative stress and cell proliferation
S Immenschuh (2005)
Expression of peroxiredoxin and thioredoxin in human lung cancer and paired normal lung.
J. Park (2005)
Dual Role of Peroxiredoxin I in Macrophage-derived Foam Cells*
J. P. Conway (2006)
Human prx1 gene is a target of Nrf2 and is up-regulated by hypoxia/reoxygenation: implication to tumor biology.
Yun-Jeong Kim (2007)
Elevated Peroxiredoxin 1, but not NF-E2–Related Factor 2, Is an Independent Prognostic Factor for Disease Recurrence and Reduced Survival in Stage I Non–Small Cell Lung Cancer
Joo-Heon Kim (2007)
Oxidative stress and antioxidant status in cervical cancer patients
M. Naidu (2007)
This paper is referenced by
The critical role of peroxiredoxin-2 in colon cancer stem cells
Linglong Peng (2021)
PRDX2 Promotes the Proliferation and Metastasis of Non-Small Cell Lung Cancer In Vitro and In Vivo
Y. Chen (2020)
Celastrol induces ROS-mediated apoptosis via directly targeting peroxiredoxin-2 in gastric cancer cells
Xi Chen (2020)
siPRDX 2-elevated DNM 3 inhibits the proliferation and metastasis of colon cancer cells via AKT signaling pathway
Yini Ma (2019)
siPRDX2-elevated DNM3 inhibits the proliferation and metastasis of colon cancer cells via AKT signaling pathway
Yini Ma (2019)
Up-regulation of peroxiredoxin 3 by high-risk human papillomavirus in cervical cancer cells
Xiao-juan Sun (2019)
Catalytic and Signaling Role of Peroxiredoxins in Carcinogenesis
M. Sharapov (2019)
Y. Ma (2019)
Expression of thioredoxin 1 and peroxiredoxins in squamous cervical carcinoma and its predictive role in NACT
Haiyan Zhu (2019)
The prognostic values of the peroxiredoxins family in ovarian cancer
Integrative machine learning analysis of multiple gene expression profiles in cervical cancer
M. S. Tan (2018)
Peroxiredoxin Involvement in the Initiation and Progression of Human Cancer.
M. Hampton (2017)
Studies induced carcinogenicity in mouse skin : A proteomic approach
J. George (2018)
Disruption of the c-Myc/miR-200b-3p/PRDX2 regulatory loop enhances tumor metastasis and chemotherapeutic resistance in colorectal cancer
Z. Lv (2017)
Cervical Cancer Cell Line Secretome Highlights the Roles of Transforming Growth Factor-Beta-Induced Protein ig-h3, Peroxiredoxin-2, and NRF2 on Cervical Carcinogenesis
G. Kontostathi (2017)
Peroxiredoxin 1 – an antioxidant enzyme in cancer
Chenbo Ding (2016)
Mitochondrial ROS control of cancer.
M. D. Idelchik (2017)
The role of peroxiredoxins in cancer
A. Nicolussi (2017)
High-Protein Intake during Weight Loss Therapy Eliminates the Weight-Loss-Induced Improvement in Insulin Action in Obese Postmenopausal Women.
G. Smith (2016)
Roles of peroxiredoxins in cancer, neurodegenerative diseases and inflammatory diseases
M. H. Park (2016)
The application of proteomics in different aspects of hepatocellular carcinoma research.
Xiaohua Xing (2016)
Expression and function of peroxiredoxins in gynecological malignancies.
Wenwen Zhang (2016)
PRDX 2 protects hepatocellular carcinoma SMMC-7721 cells from oxidative stress
Silei Zhou (2016)
PRDX2 protects hepatocellular carcinoma SMMC-7721 cells from oxidative stress.
S. Zhou (2016)
Anti-cancer effect of snake venom toxin through down regulation of AP-1 mediated PRDX6 expression
H. Lee (2015)
Plasma nuclear factor kappa B and serum peroxiredoxin 3 in early diagnosis of hepatocellular carcinoma.
S. Ismail (2015)
The functional role of peroxiredoxin 3 in reactive oxygen species, apoptosis, and chemoresistance of cancer cells
Lianqin Li (2015)
Redox control of viral carcinogenesis: The human papillomavirus paradigm.
C. Foppoli (2015)
Prognostic biomarkers for HNSCC using quantitative real‐time PCR and microarray analysis: β‐tubulin isotypes and the p53 interactome
S. Lobert (2014)
Regulation of the ROS response dynamics and organization to PDGF motile stimuli revealed by single nanoparticle imaging.
C. Bouzigues (2014)
Serum peroxiredoxin3 is a useful biomarker for early diagnosis and assessemnt of prognosis of hepatocellular carcinoma in Chinese patients.
L. Shi (2014)
Paclitaxel-resistant HeLa cells have up-regulated levels of reactive oxygen species and increased expression of taxol resistance gene 1.
Wenxiang Bi (2014)See more